Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 168

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel

Open access
Wee, Zhen Ning, Yatim, Siti Maryam J. M., Kohlbauer, Vera K, Feng, Min, Goh, Jian Yuan, Bao, Yi, Lee, Puay Leng, Zhang, Songjing, Wang, Pan Pan, Lim, Elgene, Tam, Wai Leong, Cai, Yu, Ditzel, Henrik J, Hoon, Dave S. B., Tan, Ern Yu, Yu, Qiang·2015·Nature Communications

Abstract

Metastatic tumour recurrence due to failed treatments remains a major challenge of breast cancer clinical management. Here we report that interleukin-1 receptor-associated kinase 1 (IRAK1) is overexpressed in a subset of breast cancers, in particular triple-negative breast cancer (TNBC), where it acts to drive aggressive growth, metastasis and acquired resistance to paclitaxel treatment. We show that IRAK1 overexpression confers TNBC growth advantage through NF-κB-related cytokine secretion and metastatic TNBC cells exhibit gain of IRAK1 dependency, resulting in high susceptibility to genetic and pharmacologic inhibition of IRAK1. Importantly, paclitaxel treatment induces strong IRAK1 phosphorylation, an increase in inflammatory cytokine expression, enrichment of cancer stem cells and acquired resistance to paclitaxel treatment. Pharmacologic inhibition of IRAK1 is able to reverse paclitaxel resistance by triggering massive apoptosis at least in part through inhibiting p38-MCL1 pro-survival pathway. Our study thus demonstrates IRAK1 as a promising therapeutic target for TNBC metastasis and paclitaxel resistance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ncomms9746

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 8 references

Cited by

See all 168

Metadata

Authors
Wee, Z. N., Yatim, S. M. J. M., Kohlbauer, V. K., Feng, M., Goh, J. Y., Bao, Y., Lee, P. L., Zhang, S., Wang, P. P., Lim, E., Tam, W. L., Cai, Y., Ditzel, H. J., Hoon, D. S. B., Tan, E. Y., & Yu, Q.
Venue
Nature Communications
Published
2015-10-27
Volume
6
Issue
1
Pages
8746-8746
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2260138955
Cited by
168
References
8
FWCI
2.85
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel. https://app.cochat.ai/papers/10.1038/ncomms9746
The paper
Wee, Z. N., Yatim, S. M. J. M., Kohlbauer, V. K., Feng, M., Goh, J. Y., Bao, Y., Lee, P. L., Zhang, S., Wang, P. P., Lim, E., Tam, W. L., Cai, Y., Ditzel, H. J., Hoon, D. S. B., Tan, E. Y., & Yu, Q. (2015). IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel. Nature Communications. https://doi.org/10.1038/ncomms9746

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.